Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at Americ
-
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
-
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
-
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
-
Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma
-
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
-
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
-
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Expositio
-
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
-
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
-
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
-
Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors
-
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
-
ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American Society of Hematology Annual Meeting
-
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
-
Scryb Launches New AI Governance Technology Business Unit, 'Raidian'
-
Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged
-
Storyinstanavigation Ranks the Top 5 Best Instagram Story Viewers Online
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
-
CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company's 2024 Annual General Meeting Materials
-
Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
-
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leuke
-
Siemon Releases 2024 ESG Report: A Commitment to Sustainability
-
Notice of Convening Hearing
-
Max Stock Limited: Immediate report of changes to interested party holdings
-
National Press Club: Family Of Austin Tice Available for Interviews at St. John's Church
-
Remarkable Determination: A Contestant Submitted 200 Entries, Yet None Reached The Longlist
-
Renovate.com Bridges Home Improvement Gap by Prequalifying Financing and Connecting Homeowners With Contractors
-
XMX LONDON LIMITED Celebrates 20 Years of Excellence in High End Residential Construction and Commercial Building Development
-
Nanning: A Colorful City of Cultural Diversity
-
Monster Energy's David Wise Claims Third Place in Men's Freeski Halfipe at the FIS World Cup at China's Secret Garden
-
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
-
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
-
FinCEN and DOJ Appeal Corporate Transparency Act Nationwide Injunction Two Days After Texas Ruling on BOIR
-
Vision Marine and Armada Partner to Produce an Innovative Electric Pontoon for North America’s Regulated Lakes
-
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
-
RBB Law Group Partners with Amazon to Transform Car Buying and Ensure Fair Rebates Nationwide
-
EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
-
DKbitex to Launch DKBC: A Revolutionary New Cryptocurrency
-
Hosted.com Launches AI-Powered Domain Name Generator, Simplifying The Domain Registration Process
-
Staking AI Redefines Crypto Investments: Discover the Highest APY Platform of 2024
-
ZeusX Celebrates Milestones in Connecting Gamers Through a Secure Marketplace
-
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
-
Icona Capital Acquires Island In Maldives for an Ultra-Luxury Project
-
Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times
-
DKbitex to Launch DKDC: A Revolutionary New Cryptocurrency
-
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
